A2 BIO Trademark

Trademark Overview


On Thursday, October 14, 2021, a trademark application was filed for A2 BIO with the United States Patent and Trademark Office. The USPTO has given the A2 BIO trademark a serial number of 97074028. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Monday, December 1, 2025. This trademark is owned by A2 Biotherapeutics, Inc.. The A2 BIO trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:

Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and preventi...

Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases;

Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease;
a2 bio

General Information


Serial Number97074028
Word MarkA2 BIO
Filing DateThursday, October 14, 2021
Status730 - FIRST EXTENSION - GRANTED
Status DateMonday, December 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 4, 2023

Trademark Statements


Goods and ServicesTherapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases
NOT AVAILABLE"BIO"
Pseudo MarkA TWO BIO
Goods and ServicesIdentification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases;
Description of MarkThe mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Goods and ServicesManufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease;

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 3, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateWednesday, November 3, 2021
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 3, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameA2 Biotherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAgoura Hills, CA 91301

Party NameA2 Biotherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAgoura Hills, CA 91301

Trademark Events


Event DateEvent Description
Monday, October 18, 2021NEW APPLICATION ENTERED
Wednesday, November 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 4, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, July 13, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 13, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 13, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 20, 2022ASSIGNED TO EXAMINER
Friday, July 22, 2022NON-FINAL ACTION WRITTEN
Friday, July 22, 2022NON-FINAL ACTION E-MAILED
Friday, July 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 23, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 23, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 24, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, February 25, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 17, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 17, 2023SOU EXTENSION 1 FILED
Friday, November 17, 2023SOU EXTENSION 1 GRANTED
Tuesday, November 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 14, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 14, 2024SOU EXTENSION 2 FILED
Tuesday, May 14, 2024SOU EXTENSION 2 GRANTED
Wednesday, May 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 7, 2024SOU TEAS EXTENSION RECEIVED
Thursday, November 7, 2024SOU EXTENSION 3 FILED
Thursday, November 7, 2024SOU EXTENSION 3 GRANTED
Thursday, November 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 19, 2025SOU TEAS EXTENSION RECEIVED
Monday, May 19, 2025SOU EXTENSION 4 FILED
Tuesday, May 20, 2025SOU EXTENSION 4 GRANTED
Tuesday, May 20, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 7, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 30, 2025TEAS REQUEST TO DIVIDE RECEIVED
Friday, May 30, 2025DIVISIONAL REQUEST RECEIVED
Monday, November 10, 2025DIVISIONAL PROCESSING COMPLETE
Monday, November 10, 2025CORRECTED NOA E-MAILED
Monday, November 24, 2025SOU TEAS EXTENSION RECEIVED
Monday, November 24, 2025SOU EXTENSION 1 FILED
Monday, December 1, 2025SOU EXTENSION 1 GRANTED
Tuesday, December 2, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED